“When the price of a drug suddenly goes up by several hundred percent, this is something the Commission may look at” Commissioner Vestager said when opening a formal investigation into Aspen’s alleged excessive pricing conduct in May 2017. On 10 February 2021, the EU Commission (Commission) closed the investigation by accepting legally binding commitments offered by Aspen which remove its concerns over excessive pricing. Under these commitments: Aspen agreed to reduce its prices across Europe for each of the drugs involved by an average of 73%, thereby reducing the prices to below 2012 levels, when it acquired the drugs and gradually started to increase their prices; Aspen will not be permitted to increase its prices for a 10 year period (with the exception of a possible review after
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.